In conclusion, our study shows that, as assessed with our high-throughput quantitative immunohistochemical procedure in TMAs from 924 breast cancers, c Kit was expressed in 14.7% of patients and was predictive of patients' outcome, and also in node-negative subsets. This evidence concerns the gene KIT and breast carcinoma.